A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014)
poster
posted on 2020-03-01, 16:17 authored by Shijie RenShijie Ren, Katy Cooper, James CooperJames Cooper, Helen SmithHelen Smith, Soraya Shaikh<p>Parkinson’s disease affects about 110,000 people in the UK
and 1.25 million people in Europe.1
Current options for management of advanced Parkinson’s disease include: </p>
<p>• Increased dose or frequency of immediate-release levodopa
(IR LD)</p>
<p> • Supplemental
controlled-release levodopa (CR LD)</p>
<p> • Adjunctive
therapies with levodopa, including dopamine agonists, monoamine oxidase-B
inhibitors (MAO-BIs), and catechol-O-methyl transferase inhibitors (COMTIs) A
new modified release form of levodopa (IPX066) is in development. </p>
History
Ethics
- There is no personal data or any that requires ethical approval
Policy
- The data complies with the institution and funders' policies on access and sharing
Sharing and access restrictions
- The data can be shared openly
Data description
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files
